argenx to Highlight Key Programs from Neuromuscular : vimars

Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases ...

Related Keywords

Japan , Tennessee , United States , Netherlands , Amsterdam , Noord Holland , American , Nancyl Kuntz , Richarda Lewis , Cynthia Qi , Demyelinating Polyneuropathy , Glenn Phillips , Gordon Smith , Tania Beltran Papsdorf , Deborah Gelinas , Jamesf Howard Jr , Tuan Vu , Srikanth Muppidi , Kelly Gwathmey , Tim Van Hauwermeiren , Us National Research Databases , Myasthenia Gravis Foundation Of America , Drug Administration , American Association Of Neuromuscular , American Association , Electrodiagnostic Medicine , Annual Meeting , Myasthenia Gravis Foundation , Scientific Session , Chief Executive Officer , Myasthenia Gravis Activities , Daily Living , Quantitative Myasthenia Gravis , Treatment Burden , Term Safety , Generalized Myasthenia Gravis , Interim Results , Patients Receiving , Fixed Cycle Dosing , Intravenous Efgartigimod , Study Design , Juvenile Generalized Myasthenia , Generalized Myasthenia , Integrated Interim Analysis , Efgartigimod Treatment , Cellular Immune Responses , T Cell Dependent Antibody Response , Infection Risk , Chronic Inflammatory Demyelinating Polyneuropathy , Multifocal Motor Neuropathy , Placebo Controlled Phase , Tennessee Ballroom , Intravenous Infusions , Clinical Trial , Beltran Papsdorf , Open Label Study , Risk Benefit Analysis , Efgartigimod Demonstrates Consistent Improvements , Including Early , Real World Treatment Patterns , Hospital Admissions , Prescribing Information , Important Safety , Safety Information , Brussels Stock Exchange Argx , Argenx Se ,